Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

Featuring works from Chelsea Odufu, Laurena Finéus, Jarrett Key, and more, the show challenges how we encounter personal ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

This would mark another shift in Japan’s arms industry, which so far has been largely restricted to producing equipment for ...

Other appointments to BIO's board for the 2025 through 2026 term include: Arcutis Bio's Frank Watanabe, named vice-chair; ...